Italian skin lymphoma study
Part of Cancer clinical trials.
This study aims to understand how common skin lymphomas are in Italy. You might be able to help if you have been diagnosed with a skin lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are over 2 years old
- You have been diagnosed with cutaneous lymphoma (a type of lymphoma that starts in the skin)
- You are willing to give your permission (informed consent) to participate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for adults newly diagnosed with lymphoma in the last 3 months, including those who may have started treatment. It aims to collect information on patients in Italy.
This study follows people with primary cutaneous T-cell lymphoma who are seen at the Dermatology Unit in Pavia. It collects information to better understand the disease and improve care.
This is a study that looks back and forward at people diagnosed with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or a related early condition called MBL. It aims to improve how these conditions are recognized and managed over time in Italy.
This study looks at patients with marginal zone lymphoma who were diagnosed and treated at a specific hospital in Italy between 2012 and 2018. It aims to learn more about how the disease progresses and how patients respond to treatment.
This study observes patients with certain lymphomas who are already eligible for standard CAR-T cell therapy in Italy. It aims to gather real-world information about how these treatments work.
This study looks at how people with certain immune-related skin diseases are treated in Italy. It will help doctors understand which treatments are used and why.
Hear when a new Lymphoma With Cutaneous Involvement trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.